Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (261-270 of 344) with videos related to

Pageof 35
Sort By:
Journal for Immunotherapy of Cancer|July 26, 2019
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumorsKohei Shitara, Satoshi Ueha, Shigeyuki Shichino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
JAMA Network Open|August 3, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical TrialTakaki Yoshikawa, Kei Muro, Kohei Shitara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 TherapyKeigo Chida, Akihito Kawazoe, Toshihiro Suzuki, et al.
Journal of Gastrointestinal Cancer|April 10, 2023
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction CancerKei Muro, Kohei Shitara, Kensei Yamaguchi, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Pageof 35

Showing results (261-270 of 344) with videos related to

Sort By:
Pageof 35
Journal for Immunotherapy of Cancer|July 26, 2019
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumorsKohei Shitara, Satoshi Ueha, Shigeyuki Shichino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
JAMA Network Open|August 3, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical TrialTakaki Yoshikawa, Kei Muro, Kohei Shitara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 TherapyKeigo Chida, Akihito Kawazoe, Toshihiro Suzuki, et al.
Journal of Gastrointestinal Cancer|April 10, 2023
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction CancerKei Muro, Kohei Shitara, Kensei Yamaguchi, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Pageof 35